Neovii Biotech

Executive Summary

Neovii Biotech is a private German-Swiss biopharmaceutical company specializing in polyclonal antibody-based immunosuppressive therapies for organ transplantation and hematological malignancies. Founded in 2008 and headquartered in Gräfelfing, Germany, with corporate offices in Rapperswil-Jona, Switzerland, Neovii has established itself as a global leader in the development of antibody therapies that modulate the immune system to improve transplant tolerance and target malignant cells. The company's proprietary platform leverages polyclonal antibodies, which offer broad and potent immunomodulatory effects, distinguishing it from monoclonal approaches. Neovii's pipeline focuses on addressing significant unmet needs in transplant rejection and hematologic cancers, areas where current treatments often carry high toxicity or limited efficacy. As a privately held entity, Neovii has not disclosed its total funding or valuation, but its specialized expertise and long-standing presence in the field suggest a strong competitive position in the niche of polyclonal antibody therapeutics. The company's ongoing research aims to expand its product portfolio and advance clinical programs targeting key immunological pathways.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for lead polyclonal antibody in transplant rejection45% success
• Q4 2026Partnership or licensing deal for hematology/oncology candidate30% success
• Q2 2026Publication of preclinical data supporting new indication60% success